Premium
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
Author(s) -
Nishikawa Go,
Booth Christopher,
Prasad Vinay
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32979
Subject(s) - olaparib , medicine , pancreatic cancer , cancer , clinical trial , oncology , polymerase , poly adp ribose polymerase , gene , biochemistry , chemistry
Because of the lack of a survival benefit, the suboptimal control arm design, and the overall health care costs, the authors do not believe that olaparib represents a major advance for patients with pancreatic cancer. The POLO trial illustrates that as a community, even in settings where there is a huge need, physicians must be rigorous in their methodology and mindful that they not lower the bar for new therapies.